BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17144165)

  • 21. Secretion and lysophospholipase D activity of autotaxin by adipocytes are controlled by N-glycosylation and signal peptidase.
    Pradère JP; Tarnus E; Grès S; Valet P; Saulnier-Blache JS
    Biochim Biophys Acta; 2007 Jan; 1771(1):93-102. PubMed ID: 17208043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity.
    Ferguson CG; Bigman CS; Richardson RD; van Meeteren LA; Moolenaar WH; Prestwich GD
    Org Lett; 2006 May; 8(10):2023-6. PubMed ID: 16671772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ATX-LPA receptor axis in inflammation and cancer.
    Liu S; Murph M; Panupinthu N; Mills GB
    Cell Cycle; 2009 Nov; 8(22):3695-701. PubMed ID: 19855166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autotaxin: a protein with two faces.
    Tania M; Khan MA; Zhang H; Li J; Song Y
    Biochem Biophys Res Commun; 2010 Oct; 401(4):493-7. PubMed ID: 20888793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of autotaxin/lysophospholipase D activity.
    Morris AJ; Smyth SS
    Methods Enzymol; 2007; 434():89-104. PubMed ID: 17954243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid.
    Dusaulcy R; Rancoule C; Grès S; Wanecq E; Colom A; Guigné C; van Meeteren LA; Moolenaar WH; Valet P; Saulnier-Blache JS
    J Lipid Res; 2011 Jun; 52(6):1247-1255. PubMed ID: 21421848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration.
    Ptaszynska MM; Pendrak ML; Stracke ML; Roberts DD
    Mol Cancer Res; 2010 Mar; 8(3):309-21. PubMed ID: 20197381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
    Samadi N; Gaetano C; Goping IS; Brindley DN
    Oncogene; 2009 Feb; 28(7):1028-39. PubMed ID: 19079345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.
    Umezu-Goto M; Kishi Y; Taira A; Hama K; Dohmae N; Takio K; Yamori T; Mills GB; Inoue K; Aoki J; Arai H
    J Cell Biol; 2002 Jul; 158(2):227-33. PubMed ID: 12119361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
    Li S; Wang B; Xu Y; Zhang J
    Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lysophosphatidic acid is a lipid mediator with wide range of biological activities. Biosynthetic pathways and mechanism of action.
    Berdichevets IN; Tyazhelova TV; Shimshilashvili KhR; Rogaev EI
    Biochemistry (Mosc); 2010 Sep; 75(9):1088-97. PubMed ID: 21077828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lysophospholipids in the limelight: autotaxin takes center stage.
    Moolenaar WH
    J Cell Biol; 2002 Jul; 158(2):197-9. PubMed ID: 12135981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors.
    Tabchy A; Tigyi G; Mills GB
    Nat Struct Mol Biol; 2011 Feb; 18(2):117-8. PubMed ID: 21289650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.
    Ma L; Uchida H; Nagai J; Inoue M; Chun J; Aoki J; Ueda H
    Mol Pain; 2009 Nov; 5():64. PubMed ID: 19912636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.
    Inoue M; Xie W; Matsushita Y; Chun J; Aoki J; Ueda H
    Neuroscience; 2008 Mar; 152(2):296-8. PubMed ID: 18280050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
    Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
    J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
    Zhang R; Wang J; Ma S; Huang Z; Zhang G
    BMC Cell Biol; 2011 Mar; 12():11. PubMed ID: 21406114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization of a pipemidic acid autotaxin inhibitor.
    Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
    J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs.
    Kanda H; Newton R; Klein R; Morita Y; Gunn MD; Rosen SD
    Nat Immunol; 2008 Apr; 9(4):415-23. PubMed ID: 18327261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
    Federico L; Pamuklar Z; Smyth SS; Morris AJ
    Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.